Clinical Trials Browser

Glucagonoma × Everolimus × Endocrine × Clear all

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Glucagonoma, Insulinoma, Melanoma, Pheochromocytoma, Somatostatinoma, Carcinoma, Merkel Cell, Gastrinoma, Carcinoma, Islet Cell, Carcinoma, Medullary

NCT02031536 2023-06-29

Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery

Phase 2 Terminated

2 enrolled 8 charts

Endocrine

Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

NCT02273752 2017-02-03

Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer

Phase 2 Terminated

2 enrolled 5 charts

BreastEndocrineGenitourinaryOther

Breast Neoplasms, Carcinoma, Renal Cell, Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Mucositis

NCT01204476 2016-07-15

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

Phase 1 Completed

27 enrolled

CNSDermatologicEndocrine

Glucagonoma, Insulinoma, Paraganglioma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary

Clinical Trials

Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors

Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery

Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma